Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the

... Read more

Achillion Reports 100%

... Read more

Acorda Therapeutics to

... Read more

Acorda Therapeutics to

... Read more

Acorda Announces Positive Phase 3 Clinical Trial Results for

... Read more

Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 Trial

NEW YORK - September 20, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc.

... Read more

Actinium Receives Orphan-Drug Designation From FDA for Actimab-A in the

... Read more

Read more

Read more

Actinium

... Read more